ReviewFrontiers in oncology2026
Clinical characteristics and management of renal solitary fibrous tumors: a narrative review with literature-derived case evidence.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Renal solitary fibrous tumor is a rare mesenchymal neoplasm with heterogeneous biological behavior. This review summarizes current evidence regarding its epidemiology, diagnosis, treatment, and clinical outcomes to support clinical management. Methods: PubMed and Web of Science were searched from database inception to September 10, 2025, for studies involving renal solitary fibrous tumors. Eligible studies included case reports, case series, and original articles providing patient-level data on clinically and histologically confirmed primary renal solitary fibrous tumors. Results: Renal solitary fibrous tumors commonly originate from the renal capsule or sinus and are frequently asymptomatic, although flank pain and hematuria may occasionally be present. Diagnostically, imaging typically reveals a well-circumscribed mass with variable enhancement patterns; however, histopathological examination remains essential for definitive diagnosis, characterized by spindle-cell proliferation and diffuse nuclear expression of STAT6. Therapeutically, complete surgical excision with negative margins constitutes the mainstay of treatment and is associated with favorable outcomes in the majority of patients. Nevertheless, approximately 10-15% of cases may develop recurrence or distant metastasis, underscoring the necessity of long-term surveillance. In the setting of advanced disease, limited data suggest that metastasectomy and selected targeted or anti-angiogenic agents may offer therapeutic benefit. Conclusion: Accurate diagnosis requires integrated clinical, radiologic, and pathologic evaluation. Complete resection remains the cornerstone of treatment, while prolonged follow-up is recommended because of the potential for delayed recurrence. Further molecular studies and collaborative investigations are needed to optimize risk stratification and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.